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Glycoconjugates play essential roles in cell recognition, infectivity and survival of protozoan parasites
within their insect vectors and mammalian hosts. b-galactofuranose is a component of several glycocon-
jugates in many organisms, including a variety of trypanosomatids, but is absent in mammalian and Afri-
can trypanosomes. Herein, we describe the presence of a b(1–3) galactofuranosyl transferase (GALFT), an
important enzyme of the galactofuranose biosynthetic pathway, in Trypanosoma rangeli. The T. rangeli
GALFT gene (TrGALFT) has an ORF of 1.2 Kb and is organized in two copies in the T. rangeli genome. Anti-
bodies raised against an internal fragment of the transferase demonstrated a 45 kDa protein coded by
TrGALFT was localized in the whole cytoplasm, mainly in the Golgi apparatus and equally expressed in
epimastigotes and trypomastigotes from T. rangeli. Despite the high sequence similarity with Trypano-
soma cruzi and Leishmania spp. orthologous TrGALFT showed a substitution of the metal-binding DXD
motif, conserved amongst glycosyltransferases, for a DXE functionally analogous motif. Moreover, a
reduced number of GALFT genes were present in T. rangeli when compared with other pathogenic kine-
toplastid species.
 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction The metabolic pathways involved in the removal or attachmentThe carbohydrates present in glycoconjugates of the cell surface
of trypanosomatids are essential to a variety of cell events, including
infectivity and/or virulence in insect vectors andmammalian hosts.
Among these, galactofuranose, a glycoside present in most patho-
genic trypanosomatids, fungi and bacteria but absence inmammals,
represents an interesting target for therapeutic approaches of sev-
eral diseases related to these organisms (de Lederkremer and Colli,
1995; Oppenheimer et al., 2011; Pedersen and Turco, 2003; Shibata
and Okawa, 2011). In Trypanosoma cruzi, galactofuranose is found in
the lipopeptidophosphoglycan (LPPG) coat (de Lederkremer et al.,
1980, 1985; Golgher et al., 1993), in mucins and other proteins,
including the 80–90 kDa glycoproteins and glycopeptides involved
in host cell adhesion and parasite internalization (De Arruda et al.,
1989; Haynes et al., 1996; Serrano et al., 1995). Galactofuranose is
also present in Leishmania spp. glycoconjugates related to parasite
structure, such as lipophosphoglycans (LPG) (McConville et al.,
1990; Previato et al., 1997; Turco and Descoteaux, 1992).oco), cassandraaresi@hotmail.
eyer), maisamichels@hotmail.
cero), mario.steindel@ufsc.br
dmundo.grisard@ufsc.br (E.C.
sevier OA license.of galactofuranose from trypanosomatids glycoconjugates have
been reported, including a T. cruzi exo b-D-galactofuranosidase
(Miletti et al., 2003). Genes encoding b(1–3) galactofuranosyl
transferase (GALFT) enzymes have been described for T. cruzi
(El-Sayed et al., 2005) and Leishmania spp. (Ivens et al., 2005; Spãth
et al., 2000; Zhang et al., 2004), but expression and protein charac-
terization was achieved only for Leishmania sp. On the other hand,
the absence of GALFT in African trypanosomes remains an intrigu-
ing question (Berriman et al., 2005).
Considering the importance of galactofuranose glycoconjugates
for mammalian pathogenic trypanosomatids, in this work, we de-
scribed for the ﬁrst time the presence of GALFT in the protozoan
parasite Trypanosoma rangeli. This parasite infects a variety of
mammalian species, including humans in Central and South Amer-
ica, and probably has an impact on the misdiagnosis of Chagas dis-
ease (Grisard et al., 1999a, 2010).
After colonization of the triatomine vector gut, the parasites
reach the hemocoel, where the epimastigotes multiplicate in the
hemolymph, invade the salivary glands and transform into meta-
cyclic trypomastigotes (D’Alessandro, 1976; Grisard et al., 1999b;
Guhl and Vallejo, 2003). Transmission to the mammalian host oc-
curs by the bite of infected triatomines, in particular those from the
genus Rhodnius. Although T. rangeli is considered pathogenic to the
invertebrate host, this parasite is completely harmless to the mam-
malian host, where its biology, including intracellular multiplica-
tion ability, remains controversial.
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mine bugs are well known (Grisard et al., 1999a, 2010; Guhl and
Vallejo, 2003), the parasite development in the mammalian host
remains unknown. This lack of information emphasizes the need
for further studies into the parasite–host cell interaction, where
galactofuranose glycoconjugates might play an important role. As
several glycoconjugates have important roles in cell–parasite
interactions in pathogenic protozoa, the expression of beta galacto-
furanosyl transferase, a key enzyme in the galactofuranose path-
way, was investigated in the non-pathogenic parasite T. rangeli.2. Materials and methods
2.1. Parasites and culture conditions
Epimastigotes of T. rangeli Choachí strain and T. cruzi Y strain
were maintained in liver infusion tryptose (LIT) medium
supplemented with 10% FCS at 27 C after cyclic passages in mice-
triatomine-mice. Differentiation of T. rangeli epimastigotes to try-
pomastigotes was accomplished in vitro under chemically deﬁned
conditions, as described previously (Koerich et al., 2002).
T. cruzi trypomastigotes were obtained from the supernatant of
Vero cells (ATCC-CCL81) cultures infected with bloodstream trypo-
mastigote forms and maintained in Dulbecco’s modiﬁed Eagle’s
Medium – DMEM (Sigma–Aldrich), pH 7.4, supplemented with
5% FCS (Carvalho and De Souza, 1983; Eger-Mangrich et al., 2001).
2.2. T. rangeli DNA and RNA isolation
Total DNA was puriﬁed using 2  108 T. rangeli epimastigotes by
standard phenol–chloroform procedures. Total RNA was obtained
using the Trizol reagent (Invitrogen). Messenger RNA (mRNA)
was puriﬁed using the lMACs mRNA Isolation (Miltenyi Biotec).
Assessment of purity and quality was performed spectrophotomet-
rically (260/280 nm) and by ethidium bromide-stained agarose gel
electrophoresis.
2.3. Cloning and sequencing of TrGALFT gene
Using T. rangeli transcriptome data (Grisard et al., 2010), two
primers (GalF 50-GAG CTT GAG AAG ATT TAT GGG TGG-30/GalR
50-GTT CTC GTC AAA ATA TCC CAC CG-30) were designed to obtain
the entire 1.2 Kb of the T. rangeli b-galactofuranosyl transferase
gene sequence by RT-PCR using SuperScript II reverse transcrip-
tase (RT) (Invitrogen). Ampliﬁcation of the 50 and 30 ends of
TrGALFT cDNA was performed using the speciﬁc primers and a pri-
mer directed to the spliced leader sequence (50-CCC GAA TTC TGT
ACT ATA TTG GT-30) or an oligo(dT)35 primer (Invitrogen).
All ampliﬁcation products were cloned in pGEM-T-Easy vector
(Promega) and sequenced on both strands in a Megabace 1000
DNA Analysis System using the DYEnamic ET terminators kit (GE
Healthcare) according to the manufacturer’s conditions.
2.4. Sequence assembling and analysis
All high quality DNA sequences (Phred P20) were assembled
and analyzed using the Phred/Phrap/Consed package (Ewing and
Green, 1998) and then compared with public databases using the
BLAST algorithm (Altschul et al., 1997). Analysis of deduced protein
sequences was carried out using the Proteomic Tools provided by
the ExPASy (http://www.expasy.org). Amino acid sequences of
other kinetoplastid species GALFT’s were retrieved from the TriT-
rypDB (Aslett et al., 2010) for comparative and phylogenetic anal-
ysis (Supplementary material). Multiple alignments of amino acid
sequences were performed using CLUSTAL W package (Thompsonet al., 1994), leading to construction of phylogenetic trees using
neighbor joining method and bootstrap analysis by the MEGA 4.1
software (Tamura et al., 2007).
2.5. Southern blot
T. rangeli genomic DNA (15 lg/lane) was digested with TaqI,
EcoRI and PstI restriction endonucleases, separated by electropho-
resis, and transferred onto nylon membranes (Sigma–Aldrich). A
peroxidase-labeled probe was prepared using a 519 bp PCR frag-
ment (nucleotides 304–807) and the ECL Direct Nucleic Acid Label-
ing and Detection System (GE Healthcare). The membrane was
hybridized and washed using a standard protocol and developed
using the ECL kit according to the manufacturer’s directions.
2.6. Heterologous expression and antibody production
For expression, a TrGALFT gene fragment (aa 96–269) (Fig. 1)
was ampliﬁed by PCR using gene speciﬁc primers ExpGal-F (50-
CTC GAG GAG CTT GAG AAG ATT TAT GGG TGG-30) and ExpGal-R
(50-GGA TCC GTT CTC GTC AAA ATA TCC CAC CGT-30) modiﬁed with
appropriate restriction sites (the underlined nucleotides corre-
spond to XhoI and BamHI restriction sites, respectively). The
519 bp amplicon pre-digested with XhoI and BamHI, was cloned
into a pET14b expression vector (Novagen) and used to transform
Escherichia coli BL21 (DE3) competent cells.
The His6-tagged TrGALFT recombinant protein was obtained by
induction of the cells at OD600 of 0.6 with 1 mM of isopropyl-b-D-
thiogalactopyranoside (IPTG) at 27 C for 3 h. Cells were then har-
vested by centrifugation (6000g for 15 min at 4 C) and lysed using
a denaturing buffer (8 M Urea; 10 mM Tris; 100 mM NaH2PO4, pH
8.0). The samples were then incubated at 65 C to dissolve inclu-
sion bodies and centrifuged (10,000g for 30 min at 4 C). The super-
natants were submitted to puriﬁcation using Ni–NTA afﬁnity
chromatography columns (Qiagen) and the purity of the obtained
protein was assessed by 12% SDS–PAGE stained with Coomassie
brilliant blue R-250. Protein concentrations were determined by
the Bradford method using bovine serum albumin as standard.
Thepuriﬁed22 kDa recombinantTrGALFT (rTrGALFT)was subcu-
taneously inoculated inBalb/Cmice (50 lg)using Freund’s complete
adjuvant (Sigma–Aldrich), with two consecutive inoculations at
10 days intervals using Alu-Gel (Serva). Mouse serumwas collected
10 daysafter the third injectionand tested for anti-TrGALFTantibod-
ies. The UFSC Ethics Committee for Animal Care approved all proce-
dures involving experimental animals (Protocol 23080.025618/
2009-81).
2.7. Western blot
TrGALFT recombinant protein and total epimastigotes and try-
pomastigotes protein extracts (30 lg) from T. rangeli and T. cruzi
were mixed with Laemmli sample buffer, boiled for 5 min and re-
solved on 12% SDS–PAGE gels. Protein separations were transferred
onto nitrocellulose membranes (GE Healthcare) in appropriate buf-
fer (25 mM Tris; 192 mM glycine; 20% v/v methanol, pH 8.3) in a
TE 70 Semi-Dry Transfer Unit (GE Healthcare). Membranes were
then blocked with 5% non-fat milk in PBS (pH 7.4) with 0.1%
Tween-20 (PBS-T) for 1 h at room temperature. After blocking,
membranes were incubated for 1 h with anti-TrGALFT polyclonal
serum (1:500), anti-His-Tag monoclonal antibody (1:10,000) or
anti-a tubulin monoclonal antibody (1:10,000) used as loading
control. After four washes in PBS-T, membranes were incubated
for 1 h with anti-mouse IgG antibody conjugated with peroxidase
(1:10,000) (Sigma–Aldrich). Membranes were developed using
ECL reagent (GE Healthcare) and detection was achieved in radio-
graphic ﬁlms.
Fig. 1. Alignment of amino acid sequences of the Trypanosoma rangeli (TrGALFT) and Trypanosoma cruzi b-galactofuranosyl transferase genes. Black bar indicates the region
used for heterologous expression of TrGALFT. Identical residues are in gray background. Black arrows represent start and end points of the COG1216 conserved domain
related to predicted glycosyltransferases. Box indicates the DxE motif on TrGALFT.
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Cells were harvested from media by centrifugation (3000g,
10 min), washed twice in PBS, adjusted to a concentration of
1  106 cells ml1 and deposited on microscope coverslips previ-
ously treated with 0.1% of poly-L-lysine. Then, cells were ﬁxed with
4% (w/v) p-formaldehyde in PBS and permeabilized with 0.1% NP-
40. The coverslips were saturated with PBS containing 0.1% Tween-
20 and 5% dry milk powder and incubated (1 h, 37 C) with anti-
TrGALFT serum (1:50) in PBS containing 0.5% BSA. The coverslips
were washed with PBS and incubated (15 min, 37 C) with Alexa-
ﬂuor 488-conjugated goat-anti-mouse IgG (1:1000) (Molecular
Probes). After three washes in PBS, the parasites were incubated
for 5 min with PBS containing 4,6-diamidino-2-phenylindole
(DAPI) 1 lg ml1. The coverslips were mounted on microscopy
slides using an anti-fading solution (Invitrogen) and inspected by
confocal microscopy (Leica DMI6000 B).3. Results
3.1. Cloning and sequence analysis of TrGALFT
Based on Orestes proﬁles showing signiﬁcant similarity to a T.
cruzi b-galactofuranosyl transferase gene, RT-PCR allowed the iso-
lation of DNA fragment, which corresponded to the complete
TrGALFT gene sequence, including the 50 and 30 UTR regions. The
TrGALFT 1.2 Kb ORF encodes a protein of 400 amino acids with
a calculated molecular mass of 45 kDa (GenBank ID JN135044).
Comparative analysis of the amino acid TrGALFT sequence re-
vealed identities between 73% and 55% with T. cruzi orthologs. The
predicted glycosyltransferase conserved domain (COG 1216) was
found, including the region between amino acids 111–325. In this re-
gion the aminoacidmotif ‘‘FDENFYPAYFEDVEY’’ likely represents the
catalytic site, although TrGALFT contains a DxE instead of a DxDmo-
tif, the glycosyltransferases-conserved metal binding motif (Fig. 1).
Sequence search using the TriTrypDB database revealed 79 ami-
no acid sequences corresponding to b-galactofuranosyl transferasegenes. The majority of sequences were present in the T. cruzi gen-
ome (37 genes and 29 pseudogenes) that showed a high intra-spe-
ciﬁc conservancy. The same analysis against Leishmania spp.
revealed three distinct groups of orthologous genes that were
found in L. major, L. mexicana, L. infantum and L. braziliensis gen-
omes with variable similarities. In contrast, only two gene copies
were detected in the T. rangeli genome by Southern blot assay
using a speciﬁc probe for the TrGALFT (Fig. 2A).
Phylogenetic analysis based on amino acid sequences of b-
galactofuranosyl transferases from distinct species, excluding T.
cruzi pseudogenes, grouped T. rangeli sequence closely to T. cruzi
orthologs (Fig. 2B).
3.2. Expression and puriﬁcation of TrGALFT fragment
The His-tagged rTrGALFT protein fragment was expressed in
Escherichia coli. Since rTrGALFT was largely insoluble, puriﬁcation
from bacterial inclusion bodies was performed by standard meth-
ods. After successful puriﬁcation and refolding, a protein band with
a relative molecular mass of 22 kDa was evidenced in SDS–PAGE
(Fig. 3A) as also conﬁrmed by Western blot (Fig. 3B).
An anti-TrGALFT antiserum produced in mice was able to spe-
ciﬁcally recognize a 45 kDa polypeptide in total protein extracts
from both T. rangeli epimastigote and trypomastigote forms
(Fig. 3C). Pre-immune serum was assayed with puriﬁed rTrGALFT
and T. rangeli epimastigotes lysate as negative controls (data not
shown). This result proves the expression of a GALFT by T. rangeli
as initially pointed out by a transcriptome analysis (Grisard et al.,
2010). Based on the sequence difference and the rationale for het-
erologous expression, no recognition was observed for total pro-
tein extracts of both T. cruzi biological forms (Fig. 3C).
3.3. Immunoﬂuorescence assays (IFA)
Assessment of the subcellular localization of TrGALFT in T. ran-
geli epimastigotes and trypomastigotes by IFA showed a dispersed
cytoplasmatic distribution for both forms of the parasite (Fig. 4).
Fig. 2. (A) Genomic organization of TrGALFT gene. Schematic representation of the gene arrangement and Southern blot analysis of genomic DNA using speciﬁc probe for
TrGALFT. (B) Phylogenetic analysis of deduced amino acid sequences of b-galactofuranosyl transferase from T. rangeli and other kinetoplastid species by the Neighbor joining
method using MEGA 4.1 software. For sequence details please refer to Supplementary material.
Fig. 3. Expression of T. rangeli b-galactofuranosyl transferase (TrGALFT). (A) Heterologous expression and puriﬁcation of a recombinant fragment of TrGALFT (rTrGALFT) by
afﬁnity chromatography as revealed by 12% SDS–PAGE stained with Coomassie Blue R-250. M = molecular weight marker, 1 = total bacterial extract, 2 = ﬂow through, 3 and
4 = column washes, 5, 6 and 7 = protein elutions (250 mM imidazole). (B) Western blot of puriﬁed rTrGALFT using anti-His tag monoclonal antibody. N = Negative control
(Non-transformed bacterial extract), PGal = Puriﬁed rTrGALFT. (C) Western blot analysis of T. rangeli and T. cruzi epimastigotes (Epi) and trypomastigotes (Trypo) lysates
revealed with anti-TrGALFT serum. Alpha-tubulin was used as loading control.
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kinetoplast, suggesting the predominant presence of this enzyme
in the Golgi apparatus.4. Discussion
Considering the crucial importance of galactofuranose-contain-
ing molecules on the host cell–parasite interface for pathogenic
trypanosomatids, the present study addresses the expression of
b-galactofuranosyl transferase by T. rangeli, a non-virulent parasite,
whose life cycle in mammals is unknown.
Although several galactofuranose-containing glycoconjugates
have been found in different organisms, including pathogenic pro-
tozoa (Richards and Lowary, 2009), the presence of galactofuranose
residues in GPI-anchored proteins (Añez-Rojas et al., 2006) or muc-
ins has not been demonstrated in T. rangeli, and no studies on the
galactofuranose metabolism enzymes in this parasite have been re-
ported. In this paper, the expression of a galactofuranose metabo-
lism-related enzyme by T. rangeli, a b-galactofuranosyl transferase
is reported for the ﬁrst time.
The TrGALFT gene predicts a protein showing high similarity to
the active LPG-speciﬁc GALFT encoded by LPG1 from L. major and
other GALFTs found in other kinetoplastid species. Different from
L.major,where a transmembraneproteindomain is found in allGAL-
FTs (Zhang et al., 2004), this domainwas intriguingly absent in the T.
rangeliGALFT. Furthermore, TrGALFT sequence contains amodiﬁca-
tion of the luminal C-terminal domain with the presence of a DxE
motif instead of the canonical DxD motif found in glycosyltransfer-
ases. As pointed out by Ku et al. (2007), bothmotifs are functionally
analogous and are involved in coordinating the nucleotide sugar do-
nor-Mn(II) complex, which is important for the transferase activity.Fig. 4. Immunolocalization of b-galactofuranosyl transferase in T. rangeli epimastigotes an
Detection of anti-TrGALFT antibodies by alexa ﬂuor 488-labeled conjugate, (3) DAPI staThe simultaneous expression of different GALFTs is a common
phenomenon among some species, where different transferases
are required for distinct linkage types. For example, LPG-1, themost
studied GALFT from L. major, is responsible for adding galactofura-
nose residues to the lipophosphoglycan (LPG) core structure, but
LPG1-mutants continued to synthesize the galactofuranose-con-
taining glycosylinositolphospholipids (GIPLs) (Spãth et al., 2000).
In T. cruzi, structural studies of mucins have discovered novel link-
ages and new patterns of glycosylation, suggesting differences in
the expression and activity of speciﬁc glycosyltransferases
(Mendonça-Previato et al., 2005).
The divergence of GALFT gene copy number between T. cruzi,
which has a higher number of GALFT than T. rangeli (two copies),
is probably related to the diversity of galactofuranose-containing
glycoconjugates in each species. Comparing the variability of puta-
tive glyconconjugates, transcriptomic data of T. rangeli suggests a
reduced number of possibly glycosylated proteins when compared
with T. cruzi, including sialidases and mucins gene families, that
could be related to the non-pathogenic characteristic of T. rangeli
(Grisard et al., 2010). Indeed, the reduced number of gene copies
per gene families in T. rangeli has been suggested by EST mapping
of both parasites forms (Grisard et al., 2010).
The TrGALFT is expressed as a 45 kDa protein in epimastigote
and trypomastigote forms of the parasite. In IFA assays, the TrGAL-
FT was found dispersed in the cytoplasm, contrasting with the LPG-
1 (GALFT from L. major) localization, which is exclusively in the
Golgi apparatus. The presence of TrGALFT in the Golgi apparatus
was not excluded, since high ﬂuorescence levels were observed
close to the kinetoplast, coinciding with the localization of the Gol-
gi apparatus in this species (Zhang et al., 2004). Although TrGALFT
is similar to T. cruzi GALFTs, antibodies raised against TrGALFT
did not recognize any protein in T. cruzi extracts. This lack ofd trypomastigotes using anti-TrGALFT serum in IFA assays. (1) Light microscopy, (2)
ining and (4) merged images.
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T. cruzi or distinct epitopes between both parasites.
The expression of the TrGALFT by both epimastigotes and try-
pomastigotes corroborates with the results formerly described
for T. cruzi (Golgher et al., 1993). In T. rangeli, expression of GALFT
by epimastigotes could be related to the attachment to the midgut
surface of triatomine vector as observed for T. cruzi (Nogueira et al.,
2007), or the adherence of epimastigote forms to the gland cell
microvilli by their ﬂagella (Meirelles et al., 2005). However, in
the case of trypomastigotes, its function is unknown and may be
related to the recognition of receptors on host cells that have int-
electin-like receptors (Tsuji et al., 2001), although no evidence
has been found related to the attachment of T. rangeli in any mam-
malian cells. Since the T. rangeli life cycle within mammalian hosts
is still unknown and the host–cell parasite interplay is barely stud-
ied, but indicating that T. rangeli is probably not an intracellular
parasite, expression of molecules involved in parasite–host cell
interaction remains an intriguing question.
Since other enzymes of the galactofuranose metabolism may be
present in T. rangeli, the ongoing effort to sequence the entire par-
asite genome combined with functional genomics should reveal
important aspects of the functional role of this enzyme in the biol-
ogy of the parasite.
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